Table 1.
Bevacizumab studies in cervical cancer
| Study | Treatment | Pts | Pathology | RR (%) | P-value | PFS (ms) | HR | P-value | OS (ms) | HR | P-value | Phase |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tran et al124 | BV-CBP | 1 | SCC | 100 | na | na | na | na | na | na | na | CaRe |
| Takano et al94 | BV-CBP-P | 2 | SCC | 100 | na | na | na | na | na | na | na | Retr |
| Wright et al91 | BV-CAP or 5-FU | 6 | SCC-ADC-UND | 33 | na | na | na | na | 5.1 | na | na | Retr |
| Monk et al92 | BV | 46 | SCC-ADC | 10.9 | na | 3.4 | na | na | 7.9 | na | na | II |
| Schefter et al95 | BV-CP-RT-BRT | 49 | SCC | na | na | na | na | na | na | na | na | II |
| Tewari et al98 | BV-CHT | 227 | ADC-SCC | 48 | 0.007 | 8.2 | 0.67 | 0.0002 | 17 | 0.71 | 0.003 | |
| CHT | 225 | 36 | 5.9 | 13.3 | III | |||||||
| BV-CP-P | 115 | 50 | 0.5 | 17.5 | na | 0.03 | 17.5 | 0.68 | 0.03 | |||
| CP-P | 114 | 45 | 14.3 | |||||||||
| BV-TOP-P | 112 | 47 | 0.002 | na | na | na | 16.2 | 0.74 | 0.08 | |||
| TOP-P | 111 | 27 | 12.7 |
Abbreviations: Pts, patients; BV, bevacizumab; CBP, carboplatin; P, paclitaxel; CAP, capecitabine; 5-FU, 5-fluorouracile; CP, cisplatin; RT, radiotherapy; BRT, brachytherapy; TOP, topotecan; CHT, cisplatin – paclitaxel or cisplatin – topotecan; ADC, adenocarcinoma; SCC, squamous cell carcinoma; UND, undifferentiated; CaRe, case report; Retr, retrospective; ms, months; RR, response rate; PFS, progression-free survival; HR, hazard ratio; OS, overall survival; na, not available.